Lloyd S J, Josimovich J B, Archer D F
Am J Obstet Gynecol. 1975 May 1;122(1):85-9. doi: 10.1016/0002-9378(75)90618-3.
Administration of Brom-ergocryptine (CB-154) has a dramatic effect on breast secretion. Inhibition of lactation occurs within three to four weeks in women with amenorrhea and galactorrhea. Resumption of normal ovulatory function was documented by serum progesterone levels, as well as pregnancy, in three of four women attempting to conceive. Serum prolactin levels become normal following initiation of Brom-ergocryptine. Discontinuation of Brom-ergocryptine was found to result in a return of both inappropriate lactation and elevation of serum prolactin in this study. No deleterious side effects of Brom-ergocryptine have been found in any of the volunteers either clinically or on the basis of sequential laboratory studies.
使用溴隐亭(CB - 154)对乳汁分泌有显著影响。对于患有闭经和溢乳症的女性,在三到四周内可抑制泌乳。通过血清孕酮水平以及四名试图受孕的女性中的三名成功怀孕,记录到正常排卵功能得以恢复。开始使用溴隐亭后血清催乳素水平恢复正常。在本研究中发现,停用溴隐亭会导致不适当泌乳复发以及血清催乳素升高。在任何志愿者中,无论是临床观察还是基于连续的实验室研究,均未发现溴隐亭有有害副作用。